Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis

Hepatocellular carcinoma (HCC), the third major cause of cancer mortality, can result from non-alcoholic steatohepatitis (NASH). Due to limited efficacy of drugs approved for HCC and no drug available yet for NASH, identification of new effective treatments is crucial. Here, we investigated whether...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Pharmacol
Autori principali: Kuo, Joseph, Serrano, Sonia Simón, Grönberg, Alvar, Massoumi, Ramin, Hansson, Magnus Joakim, Gallay, Philippe
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2019
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6775500/
https://ncbi.nlm.nih.gov/pubmed/31611801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.01129
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi